Drug composition antagonistic to both pgd2/txa2 receptors

A compound of the formula (I):

• 583
• A is alkylene optionally intervened with a heteroatom, optionally having an oxo group, optionally substituted with halogen and/or optionally having an unsaturated bond;
• R is —C(═O)—R1, —CH2—R1, or tetrazolyl;
• R1 is hydroxy, alkyloxy, or optionally substituted amino;
• m is 0 or 1;
• provided that combinations wherein m is 1, A is —CH═CH—CH2—CH2—CH2— and R is —C(═O)—R1 (R1 is hydroxy or alkyloxy) and wherein A is —CH2—CH═CH—CH2—CH2—CH2— and R is —C(═O)—R1 wherein R1 is hydroxy or alkyloxy are excluded, p is 0 or 1, provided that when p=0, X1 is not bonded to X3 via X4;
• X1 and X3 are each independently optionally substituted aryl, optionally substituted heteroaryl or optionally substituted non-aromatic heterocyclyl;
• X2 is a bond, —CH2—, —CH2—CH2—, —C(═O)—, —O—, —S—, —SO—, —SO2—, —NH—, —N(CH3)—, —C(═N—O—CH3)—, —N═N—, —CH═CH—, —(C═O)—NH—, —NH—(C═O)—, —CH2—NH—, —NH—CH2—, —CH2—O—, —O—CH2—, —CH2—, —S—CH2—, —CH2—SO2—, —SO2—CH2—, —SO2—NH—, —NH—SO2—, —C(═CH2)—, —SO2N(Me)—, —CH2NHSO2—, —CH2NH—(C═O)—, —NH—C(═O)—NH or —NH—C(═O)—N(Me)—;
• X4 is —CH2—, —CH2—CH2—, —C(═O)—, —SO—, —SO2—, —(C═O)—NH—, —NH—(C═O)—, —CH2—NH—, —NH—CH2—, —CH2—O—, —O—CH2—, —CH2—S—, —S—CH2—, —CH2—SO2—, —SO2—CH2—, —SO2—NH— or —NH—SO2—,
• provided that a combination wherein
• 584
• A is —CH═CH—CH2—CH2—CH2—, R is —COOH, m is 1, p is 0, X1 and X3 are phenyl, and X2 is —N═N—, is excluded
• and provided that when
• 585
• X1 and X3 are phenyl, X2 is —CH═CH—, —O—, or —S—, m is 0, and p is 0, a compound wherein A is —CH═CH—CH2—CH2—CH2—C(CH3)2— and R is COOH, A is —CH2—C(═O)—CH2—CH2—CH2—CH2— and R is COOH, A is —CH2—CH2—CH2—CH2—CH2— and R is —COOH, or A is —CH═CH—CH2—CH2—CH2— and R is —CH2OH,
• is excluded,
• a prodrug, a pharmaceutically acceptable salt or a solvate thereof.